PEAK6’s Blueprint Medicines BPMC Stock Holding History

PEAK6’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,000	Closed	-$256K	–	2953
2025 Q2	$256K	Sell	2,000 -1,210	-38%	-$126K	﹤0.01%	2370
2025 Q1	$284K	Sell	3,210 -4,789	-60%	-$467K	﹤0.01%	2305
2024 Q4	$698K	Buy	+7,999	New	+$733K	﹤0.01%	1990

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

PEAK6's BPMC Position: Q3 2025 in Review

PEAK6 sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 2,000 shares — an estimated $256K sold.

PEAK6 first reported a position in BPMC in Q4 2024 and held it in 3 quarters. The position peaked at $698K in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

PEAK6 reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
PEAK6 sold 2,000 Blueprint Medicines shares in Q3 2025, an estimated $256K.
PEAK6 first reported a position in Blueprint Medicines in Q4 2024 and held it in 3 quarters.
PEAK6's Blueprint Medicines position peaked at $698K in Q4 2024.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.